198 related articles for article (PubMed ID: 37926727)
1. Statins abrogate gemcitabine-induced PD-L1 expression in pancreatic cancer-associated fibroblasts and cancer cells with improved therapeutic outcome.
Minz AP; Mohapatra D; Dutta M; Sethi M; Parida D; Mohapatra AP; Mishra S; Kar S; Sasmal PK; Senapati S
Cancer Immunol Immunother; 2023 Dec; 72(12):4261-4278. PubMed ID: 37926727
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer.
Kajiwara Y; Tazawa H; Yamada M; Kanaya N; Fushimi T; Kikuchi S; Kuroda S; Ohara T; Noma K; Yoshida R; Umeda Y; Urata Y; Kagawa S; Fujiwara T
Cancer Immunol Immunother; 2023 May; 72(5):1285-1300. PubMed ID: 36436021
[TBL] [Abstract][Full Text] [Related]
3. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.
Koikawa K; Kibe S; Suizu F; Sekino N; Kim N; Manz TD; Pinch BJ; Akshinthala D; Verma A; Gaglia G; Nezu Y; Ke S; Qiu C; Ohuchida K; Oda Y; Lee TH; Wegiel B; Clohessy JG; London N; Santagata S; Wulf GM; Hidalgo M; Muthuswamy SK; Nakamura M; Gray NS; Zhou XZ; Lu KP
Cell; 2021 Sep; 184(18):4753-4771.e27. PubMed ID: 34388391
[TBL] [Abstract][Full Text] [Related]
4. Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression.
Hussain SM; Kansal RG; Alvarez MA; Hollingsworth TJ; Elahi A; Miranda-Carboni G; Hendrick LE; Pingili AK; Albritton LM; Dickson PV; Deneve JL; Yakoub D; Hayes DN; Kurosu M; Shibata D; Makowski L; Glazer ES
Cell Oncol (Dordr); 2021 Jun; 44(3):673-687. PubMed ID: 33694102
[TBL] [Abstract][Full Text] [Related]
5. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma.
Daunke T; Beckinger S; Rahn S; Krüger S; Heckl S; Schäfer H; Wesch D; Pilarsky C; Eckstein M; Hartmann A; Röcken C; Wandmacher AM; Sebens S
Front Immunol; 2023; 14():1157397. PubMed ID: 37449210
[TBL] [Abstract][Full Text] [Related]
6. Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis.
Ho TTB; Nasti A; Seki A; Komura T; Inui H; Kozaka T; Kitamura Y; Shiba K; Yamashita T; Yamashita T; Mizukoshi E; Kawaguchi K; Wada T; Honda M; Kaneko S; Sakai Y
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33188035
[TBL] [Abstract][Full Text] [Related]
7. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
8. Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells.
Ebine K; Kumar K; Pham TN; Shields MA; Collier KA; Shang M; DeCant BT; Urrutia R; Hwang RF; Grimaldo S; Principe DR; Grippo PJ; Bentrem DJ; Munshi HG
Sci Rep; 2018 Sep; 8(1):13225. PubMed ID: 30185888
[TBL] [Abstract][Full Text] [Related]
9. The role of S100A9 in the interaction between pancreatic ductal adenocarcinoma cells and stromal cells.
Kung PJ; Lai TY; Cao J; Hsu LC; Chiang TC; Ou-Yang P; Tsai CY; Tsai YF; Lin CW; Chen CC; Tsai MK; Tien YW; Lee CY
Cancer Immunol Immunother; 2022 Mar; 71(3):705-718. PubMed ID: 34374812
[TBL] [Abstract][Full Text] [Related]
10. PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer.
Kawasaki K; Noma K; Kato T; Ohara T; Tanabe S; Takeda Y; Matsumoto H; Nishimura S; Kunitomo T; Akai M; Kobayashi T; Nishiwaki N; Kashima H; Maeda N; Kikuchi S; Tazawa H; Shirakawa Y; Fujiwara T
Cancer Immunol Immunother; 2023 Nov; 72(11):3787-3802. PubMed ID: 37668710
[TBL] [Abstract][Full Text] [Related]
11. Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer.
Zhang L; Yao J; Li W; Zhang C
Oncol Res; 2018 Jul; 26(6):827-835. PubMed ID: 28477403
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
[TBL] [Abstract][Full Text] [Related]
13. Hollow Cu2MoS4 nanoparticles loaded with immune checkpoint inhibitors reshape the tumor microenvironment to enhance immunotherapy for pancreatic cancer.
Yao Z; Qi C; Zhang F; Yao H; Wang C; Cao X; Zhao C; Wang Z; Qi M; Yao C; Wang X; Xia H
Acta Biomater; 2024 Jan; 173():365-377. PubMed ID: 37890815
[TBL] [Abstract][Full Text] [Related]
14. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
[TBL] [Abstract][Full Text] [Related]
15. DHA-SBT-1214 Taxoid Nanoemulsion and Anti-PD-L1 Antibody Combination Therapy Enhances Antitumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model.
Ahmad G; Mackenzie GG; Egan J; Amiji MM
Mol Cancer Ther; 2019 Nov; 18(11):1961-1972. PubMed ID: 31439714
[TBL] [Abstract][Full Text] [Related]
16. Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer.
Fang Y; Zhou W; Rong Y; Kuang T; Xu X; Wu W; Wang D; Lou W
Exp Cell Res; 2019 Oct; 383(1):111543. PubMed ID: 31374207
[TBL] [Abstract][Full Text] [Related]
17. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer.
Yin H; Pu N; Chen Q; Zhang J; Zhao G; Xu X; Wang D; Kuang T; Jin D; Lou W; Wu W
Cell Death Dis; 2021 Oct; 12(11):1033. PubMed ID: 34718325
[TBL] [Abstract][Full Text] [Related]
18. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs.
Qi R; Bai Y; Li K; Liu N; Xu Y; Dal E; Wang Y; Lin R; Wang H; Liu Z; Li X; Wang X; Shi B
Drug Resist Updat; 2023 May; 68():100960. PubMed ID: 37003125
[TBL] [Abstract][Full Text] [Related]
19. circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis.
Hu C; Xia R; Zhang X; Li T; Ye Y; Li G; He R; Li Z; Lin Q; Zheng S; Chen R
Mol Cancer; 2022 Jan; 21(1):24. PubMed ID: 35045883
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
